Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/287281
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels |
Autor: | Álvarez-Córdoba, Mónica; Reche-López, Diana; Cilleros-Holgado, Paula; Talaverón-Rey, Marta; Villalón-García, Irene; Povea-Cabello, Suleva; Suarez-Rivero, Juan M. CSIC ORCID; Suárez-Carrillo, Alejandra; Munuera, Manuel CSIC; Piñero-Perez, Rocío; Sánchez-Alcázar, José Antonio CSIC ORCID | Palabras clave: | Pantothenate kinase Pantothenate kinase-associated neurodegeneration Coenzyme A Acyl carrier protein Pantothenate Pantethine Vitamin E Omega-3 Carnitine Thiamine |
Fecha de publicación: | 2022 | Editor: | BioMed Central | Citación: | Orphanet Journal of Rare Diseases 17 (2022) | Resumen: | [Background]: Neurodegeneration with brain iron accumulation (NBIA) is a group of rare neurogenetic disorders frequently associated with iron accumulation in the basal nuclei of the brain characterized by progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and retinal degeneration or optic nerve atrophy. Pantothenate kinase-associated neurodegeneration (PKAN) is one of the most widespread NBIA subtypes. It is caused by mutations in the gene of pantothenate kinase 2 (PANK2) that result in dysfunction in PANK2 enzyme activity, with consequent deficiency of coenzyme A (CoA) biosynthesis, as well as low levels of essential metabolic intermediates such as 4′-phosphopantetheine, a necessary cofactor for essential cytosolic and mitochondrial proteins. [Methods]: In this manuscript, we examined the therapeutic effectiveness of pantothenate, panthetine, antioxidants (vitamin E and omega 3) and mitochondrial function boosting supplements (L-carnitine and thiamine) in mutant PANK2 cells with residual expression levels. [Results]: Commercial supplements, pantothenate, pantethine, vitamin E, omega 3, carnitine and thiamine were able to eliminate iron accumulation, increase PANK2, mtACP, and NFS1 expression levels and improve pathological alterations in mutant cells with residual PANK2 expression levels. [Conclusion]: Our results suggest that several commercial compounds are indeed able to significantly correct the mutant phenotype in cellular models of PKAN. These compounds alone or in combinations are of common use in clinical practice and may be useful for the treatment of PKAN patients with residual enzyme expression levels. | Versión del editor: | http://dx.doi.org/10.1186/s13023-022-02465-9 | URI: | http://hdl.handle.net/10261/287281 | DOI: | 10.1186/s13023-022-02465-9 | Identificadores: | doi: 10.1186/s13023-022-02465-9 e-issn: 1750-1172 |
Aparece en las colecciones: | (CABD) Artículos (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Therapeutic approach_ALvarez_PV_Art2022.pdf | 3,77 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
5
checked on 08-may-2024
WEB OF SCIENCETM
Citations
5
checked on 27-feb-2024
Page view(s)
29
checked on 15-may-2024
Download(s)
47
checked on 15-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons